Overview of the treatment protocol HLH-94

Slides:



Advertisements
Similar presentations
LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.
Advertisements

Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Cytotoxic therapy for severe swine flu A/H1N1
Oki Y et al. Proc ASH 2013;Abstract 252.
Cell type specific infection of Epstein–Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection  Yoshihito.
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma.
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and.
CNS involvement in DLBCL
A cell by any other name by Narla Mohandas Blood
How I treat elderly patients with myeloma
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol by Helena Trottestam, AnnaCarin Horne, Maurizio.
Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.
Advances in Biology, Diagnostics, and Treatment of Hodgkin’s Disease
Protease inhibitors potentiate chemotherapy-induced neutropenia
Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Effect of a Recombinant Dimeric Tumor Necrosis Factor Receptor on Inflammatory Responses to Intravenous Endotoxin in Normal Humans by Tom van der Poll,
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
by Alexander Röth, Andreas Hüttmann, Russell P
by Sabah Sallah, and Jim Y. Wan
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 by David Becton,
by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes by Yenan T. Bryceson, Daniela Pende, Andrea.
Blocking VWF platelet binding to treat TTP
Anergy: the CLL cell limbo
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.
Experimental Hematology
Design of the trial. Design of the trial. (1) Patients with advanced recurrent pancreatic cancer aged ≥75 years, (2) unresectable/recurrence, (3) -performance.
by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E
by Dana T. Lounder, Qiong Bin, Cristina de Min, and Michael B. Jordan
Figure 4 Aquaporin-4 immunoglobulin G (AQP4-IgG) index in time-matched paired serum-CSF specimens: 3 attack/preattack pairs and 7 bridge/remission pairs.
by Kaiwen Chen, Matthew P. Cheng, Sarah P
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Aplastic Anemia: Pathophysiology and Treatment
Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults by Paul La Rosée, AnnaCarin Horne, Melissa Hines, Tatiana von Bahr Greenwood,
Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.
Bridge to transplant following Bv+Bs regimen.
Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.
by Wendy Lim, Sara K. Vesely, and James N. George
Bv+Bs regimen schedule.
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,
Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
Response to cyclosporin A (CsA) treatment and renal outcome in patients with either nongenetic or genetic disease. Response to cyclosporin A (CsA) treatment.
How I treat hemophagocytic lymphohistiocytosis
Central nervous system–restricted familial hemophagocytic lymphohistiocytosis responds to hematopoietic cell transplantation by Hojun Li, Leslie A. Benson,
Representative staining of bone marrow aspirates collected from a patient at baseline and after 1 cycle of treatment with 45 mg/m2 selinexor + 20 mg dexamethasone,
How I treat acquired aplastic anemia
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.
Survival, subsequent therapies, and response.
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Cold agglutinin disease
Presentation transcript:

Overview of the treatment protocol HLH-94 Overview of the treatment protocol HLH-94.Day of death for the 23 patients who died the first year of therapy, except those who underwent BMT, is marked with an exclamation point (!). Overview of the treatment protocol HLH-94.Day of death for the 23 patients who died the first year of therapy, except those who underwent BMT, is marked with an exclamation point (!). (BMT = Go to BMT during continuation therapy as soon as an acceptable donor is available, preferably when the disease is nonactive. The patients without either familial or persistent disease were recommended to cease therapy after the initial therapy and restart in case of reactivation. Dexa = dexamethasone daily [pulses are 10 mg/m2 for 3 days]; VP-16 = etoposide 150 mg/m2 intravenously; CSA = cyclosporin A; I.T. therapy = intrathecal methotrexate [if progressive neurological symptoms or if an abnormal CSF has not improved].)‏ Jan-Inge Henter et al. Blood 2002;100:2367-2373 ©2002 by American Society of Hematology